Hologic, Inc. (NASDAQ:HOLX) Director Lawrence M. Levy sold 10,203 shares of the business’s stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $45.00, for a total value of $459,135.00. Following the completion of the sale, the director now owns 38,832 shares of the company’s stock, valued at $1,747,440. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded down 0.19% during mid-day trading on Friday, hitting $43.00. The stock had a trading volume of 2,648,635 shares. The stock has a 50 day moving average price of $43.64 and a 200 day moving average price of $40.87. The firm has a market cap of $12.04 billion, a PE ratio of 15.42 and a beta of 1.10. Hologic, Inc. has a 52 week low of $32.64 and a 52 week high of $46.05.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.04. The company had revenue of $715.40 million for the quarter, compared to the consensus estimate of $685.24 million. Hologic had a return on equity of 27.17% and a net margin of 11.57%. The firm’s revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.47 EPS. Equities research analysts expect that Hologic, Inc. will post $2.01 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/20/hologic-inc-holx-director-sells-459135-00-in-stock-updated.html.
HOLX has been the subject of a number of research analyst reports. Stifel Nicolaus upped their price target on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, May 11th. Leerink Swann restated an “outperform” rating and set a $52.00 price objective on shares of Hologic in a research report on Thursday, March 30th. Bank of America Corp cut Hologic from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 15th. Piper Jaffray Companies restated an “overweight” rating and set a $51.00 price objective on shares of Hologic in a research report on Tuesday, March 14th. Finally, Zacks Investment Research upgraded Hologic from a “sell” rating to a “strong-buy” rating and set a $49.00 price objective on the stock in a research report on Tuesday, April 4th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $47.54.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. TrimTabs Asset Management LLC increased its position in shares of Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares in the last quarter. Advisor Partners LLC acquired a new position in shares of Hologic during the first quarter worth about $201,000. Boston Advisors LLC acquired a new position in shares of Hologic during the third quarter worth about $202,000. Cornercap Investment Counsel Inc. acquired a new position in shares of Hologic during the fourth quarter worth about $202,000. Finally, Conning Inc. acquired a new position in shares of Hologic during the third quarter worth about $203,000. 94.09% of the stock is currently owned by institutional investors.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.